Proxima (formerly VantAI), a Roivant‑affiliated drug discovery firm, closed an $80 million seed round to fund AI‑driven discovery of proximity‑modulating therapeutics across cancer and immunology. The financing was led by DCVC and included strategic investors and Roivant affiliates. The company rebranded to Proxima and said it will use proteome‑scale structural data plus frontier AI models to design molecules that modulate protein proximity. CEO Zachary Carpenter highlighted partnerships with multiple pharma groups to accelerate lead discovery. The raise underscores investor appetite for AI‑native discovery firms focused on induced‑proximity modalities, and it signals continued early‑stage capital allocation into platform‑first biotech despite a restrained IPO market.